Nevio Taglieri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6985691/publications.pdf

Version: 2024-02-01

60 papers	1,508 citations	304743 22 h-index	315739 38 g-index
62 all docs	62 docs citations	62 times ranked	2495 citing authors

#	Article	IF	Citations
1	Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people. Journal of Nuclear Cardiology, 2022, 29, 1566-1575.	2.1	7
2	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart, 2022, 108, 54-60.	2.9	12
3	Female gender and mortality in ST-segment-elevation myocardial infarction treated with primary PCI. Journal of Cardiovascular Medicine, 2022, 23, 234-241.	1.5	5
4	Balloon pulmonary angioplasty after pulmonary thromboendarterectomy. Annals of Cardiothoracic Surgery, 2022, 11, 192-194.	1.7	3
5	Impact of Elective, Uncomplicated Target Lesion Revascularization on Cardiac Mortality After Elective Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease. American Journal of Cardiology, 2020, 128, 94-100.	1.6	0
6	Multi-Imaging Investigation to Evaluate the Relationship between Serum Cystatin C and Features of Atherosclerosis in Non-ST-Segment Elevation Acute Coronary Syndrome. Applied Sciences (Switzerland), 2019, 9, 657.	2.5	0
7	Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease. Frontiers in Pharmacology, 2019, 10, 1606.	3.5	53
8	Carbon dioxide coronary angiography: A mechanical feasibility study with a cardiovascular simulator. AIP Advances, 2018, 8, .	1.3	5
9	Prognostic significance of shockable and non-shockable cardiac arrest in ST-segment elevation myocardial infarction patients undergoing primary angioplasty. Resuscitation, 2018, 123, 8-14.	3.0	6
10	Prodromal angina and risk of 2-year cardiac mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Medicine (United States), 2018, 97, e12332.	1.0	2
11	Movement compensation during carbon dioxide coronary angiography: In-vitro validation. AIP Advances, 2018, 8, 095005.	1.3	0
12	Incidence, treatment, and outcome of acute aortic valve regurgitation complicating percutaneous balloon aortic valvuloplasty. Catheterization and Cardiovascular Interventions, 2017, 89, E145-E152.	1.7	22
13	Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1878-1887.	6.4	9
14	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension andÂAngina. Journal of the American College of Cardiology, 2017, 69, 2808-2817.	2.8	91
15	Cognitive functions: evaluation and changes after transcatheter aortic valve implantation in elderly patients. Future Cardiology, 2017, 13, 229-237.	1.2	3
16	Long-term prognostic role of cerebrovascular disease and peripheral arterial disease across the spectrum of acute coronary syndromes. Atherosclerosis, 2016, 245, 43-49.	0.8	13
17	Troponin T elevation in acute aortic syndromes: Frequency and impact on diagnostic delay and misdiagnosis. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 61-71.	1.0	26
18	Balloon aortic valvuloplasty as a bridge-to-decision in high risk patients with aortic stenosis: a new paradigm for the heart team decision making. Journal of Geriatric Cardiology, 2016, 13, 475-82.	0.2	15

#	Article	IF	Citations
19	Imaging Myocardium at Risk and Coronary Inflammation in Nonâ€“ST-Segment Elevation Myocardial Infarction. Clinical Nuclear Medicine, 2015, 40, e61-e62.	1.3	0
20	Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 1146-1153.	0.6	45
21	Long-Term Outcomes and Causes of Death After Acute Coronary Syndrome in Patients in the Bologna, Italy, Area. American Journal of Cardiology, 2015, 115, 171-177.	1.6	11
22	Impact of Gene Polymorphisms, PlateletÂReactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in PatientsÂWithÂNonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 1117-1127.	2.9	38
23	Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1807-1814.	1.6	5
24	Diagnostic performance of standard electrocardiogram for prediction of infarct related artery and site of coronary occlusion in unselected STEMI patients undergoing primary percutaneous coronary intervention. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 326-339.	1.0	22
25	Prognostic Significance of Baseline White Blood Cell Count in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. Cardiology, 2013, 125, 90-91.	1.4	0
26	Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 642-643.	6.4	0
27	Risk of stroke with percutaneous coronary intervention compared with on-pump and off-pump coronary artery bypass graft surgery: Evidence from a comprehensive network meta-analysis. American Heart Journal, 2013, 165, 910-917.e14.	2.7	34
28	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 T 792-798.	1.6	12
29	Acute kidney injury following transcatheter aortic valve implantation: incidence, predictors and clinical outcome. International Journal of Cardiology, 2013, 168, 1034-1040.	1.7	103
30	Baseline White Blood Cell Count Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome, but It Does Not Improve the Risk Classification of the GRACE Score. Cardiology, 2013, 124, 97-104.	1.4	14
31	Predictors of complicated athero-thrombotic lesions in non-ST segment acute coronary syndrome. Journal of Cardiovascular Medicine, 2013, 14, 430-437.	1.5	3
32	Detection of Tissue Factor Antigen and Coagulation Activity in Coronary Artery Thrombi Isolated from Patients with ST-Segment Elevation Acute Myocardial Infarction. PLoS ONE, 2013, 8, e81501.	2.5	21
33	Acute hand ischemia after radial intervention in patient with CREST-associated pulmonary hypertension: successful treatment with manual thromboaspiration. Journal of Invasive Cardiology, 2013, 25, 89-91.	0.4	8
34	Relation Between Angiographic Lesion Severity, Vulnerable Plaque Morphology and Future Adverse Cardiac Events (from the Providing Regional Observations to Study Predictors of Events in the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 13	1.6	43
35	What is the acceptable rate of false positives for STEMI within a primary PCI network? Insights from a metropolitan system with direct ambulance-based access. International Journal of Cardiology, 2012, 154, 356-358.	1.7	5
36	Residual aortic regurgitation is a major determinant of late mortality after transcatheter aortic valve implantation. International Journal of Cardiology, 2012, 157, 288-289.	1.7	19

#	Article	IF	Citations
37	Incidence, treatment and outcome of acute coronary syndromes: A community-based study in the era of myocardial infarction networks. International Journal of Cardiology, 2012, 157, 419-422.	1.7	3
38	Transcatheter aortic valve implantation with a selfâ€expanding nitinol bioprosthesis. Catheterization and Cardiovascular Interventions, 2012, 79, 712-719.	1.7	37
39	Is balloon aortic valvuloplasty safe in patients with significant aortic valve regurgitation?. Catheterization and Cardiovascular Interventions, 2012, 79, 315-321.	1.7	10
40	Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. Thrombosis and Haemostasis, 2011, 106, 132-140.	3.4	38
41	Short- and Long-Term Prognostic Significance of ST-Segment Elevation in Lead aVR in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 21-28.	1.6	47
42	Impact of a territorial ST-segment elevation myocardial infarction network on prognosis of patients with out-of-hospital cardiac arrest. Acute Cardiac Care, 2011, 13, 143-147.	0.2	4
43	Pre-hospital ECG in patients undergoing primary percutaneous interventions within an integrated system of care: reperfusion times and long-term survival benefits. EuroIntervention, 2011, 7, 449-457.	3.2	12
44	The role of percutaneous balloon aortic valvuloplasty as a bridge for transcatheter aortic valve implantation. EuroIntervention, 2011, 7, 723-729.	3.2	63
45	How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation?. Journal of Cardiovascular Medicine, 2010, 11, 727-732.	1.5	25
46	Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis, 2010, 209, 300-305.	0.8	55
47	Lower long-term mortality within a regional system of care for ST-elevation myocardial infarction. Acute Cardiac Care, 2010, 12, 42-50.	0.2	10
48	Percutaneous coronary intervention following thrombolysis: For whom and when?. Acute Cardiac Care, 2009, 11, 195-203.	0.2	3
49	Cystatin C and Cardiovascular Risk. Clinical Chemistry, 2009, 55, 1932-1943.	3.2	184
50	Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
51	Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. European Heart Journal, 2008, 29, 2972-2980.	2.2	41
52	Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. European Heart Journal, 2008, 30, 33-43.	2.2	45
53	Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. European Heart Journal, 2007, 29, 1241-1249.	2.2	46
54	Clinical comparison of â€œnormal-hoursâ€•vs â€œoff-hoursâ€•percutaneous coronary interventions for ST-elevation myocardial infarction. American Heart Journal, 2007, 154, 366-372.	2.7	40

#	Article	IF	Citations
55	Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheterization and Cardiovascular Interventions, 2007, 69, 790-798.	1.7	30
56	Usefulness of Prehospital Triage in Patients With Cardiogenic Shock Complicating ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 100, 787-792.	1.6	45
57	Clinical impact of direct referral to primary percutaneous coronary intervention following pre-hospital diagnosis of ST-elevation myocardial infarction. European Heart Journal, 2006, 27, 1550-1557.	2.2	86
58	32P Brachytherapy in the Treatment of Complex Cypher In-Stent Restenosis. Journal of Interventional Cardiology, 2005, 18, 205-211.	1.2	9
59	Predictors of 32P Î² brachytherapy failure in patients with high-risk in-stent restenosis. Cardiovascular Radiation Medicine, 2004, 5, 77-83.	0.6	0
60	Long-term clinical and angiographic outcome of patients with occlusive in-stent restenosis treated with (32P) ?-brachytherapy. Catheterization and Cardiovascular Interventions, 2004, 63, 433-438.	1.7	3